Pharmacological Screening Using an FXN-EGFP Cellular Genomic Reporter Assay for the Therapy of Friedreich Ataxia

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Li, Lingli ^a   Voullaire, Lucille ^a   Sandi, Chiranjeevi ^d   Pook, Mark A ^d   Ioannou, Panos A ^a,b   Delatycki, Martin B ^a,b,c   Sarsero, Joseph P ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

^d BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BENZALKONIUM CHLORIDE; BETAMETHASONE; CAMPTOTHECIN; CEFDINIR; CHEMICAL COMPOUND; CHLORPROPHAM; CHRYSANTHEMIC ACID; CISPLATIN; CLOZAPINE; CONVALLATOXIN; DEFERIPRONE; DEFEROXAMINE; DIMETHYL SULFOXIDE; ENHANCED GREEN FLUORESCENT PROTEIN; FERRIC AMMONIUM SULFATE; FERROUS AMMONIUM SULFATE; FRATAXIN; HEMIN; IRON CHELATING AGENT; MOLSIDOMINE; NIMUSTINE; PHENOTHRIN; PHYTOALEXIN; RESVERATROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BACTERIAL ARTIFICIAL CHROMOSOME; CARDIOMYOPATHY; CELL ASSAY; CELL LINE; CELLULAR GENOMIC REPORTER ASSAY; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; FIBROBLAST; FLOW CYTOMETRY; FLUOROMETRY; FRIEDREICH ATAXIA; FXN GENE; GENE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE FUSION; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INTRON; LYMPHOBLAST; MOLECULAR LIBRARY; NERVE DEGENERATION; NONHUMAN; REPORTER GENE; TRINUCLEOTIDE REPEAT; UPREGULATION;

CELL LINE; DRUG EVALUATION, PRECLINICAL; FRIEDREICH ATAXIA; GENE LIBRARY; GENES, REPORTER; GENOMICS; HELA CELLS; HUMANS; IRON-BINDING PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION; UP-REGULATION;

EID: 84873902923     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055940     Document Type: Article

References (78)

1. Pandolfo M, (2006) Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations. Methods Mol Med 126: 197-216.
2. Bidichandani SI, Ashizawa T, Patel PI, (1998) The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62: 111-121.
3. Ohshima K, Montermini L, Wells RD, Pandolfo M, (1998) Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 273: 14588-14595.
4. Grabczyk E, Usdin K, (2000) The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res 28: 2815-2822.
5. Sakamoto N, Ohshima K, Montermini L, Pandolfo M, Wells RD, (2001) Sticky DNA, a self-associated complex formed at long GAA.TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem 276: 27171-27177.
6. Delatycki MB, Camakaris J, Brooks H, Evans-Whipp T, Thorburn DR, et al. (1999) Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol 45: 673-675.
7. Cavadini P, Gellera C, Patel PI, Isaya G, (2000) Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet 9: 2523-2530.
8. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, et al. (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-186.
9. Park S, Gakh O, Mooney SM, Isaya G, (2002) The ferroxidase activity of yeast frataxin. J Biol Chem 277: 38589-38595.
10. Cavadini P, O'Neill HA, Benada O, Isaya G, (2002) Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 11: 217-227.
11. Lesuisse E, Santos R, Matzanke BF, Knight SA, Camadro JM, et al. (2003) Iron use for haeme synthesis is under control of the yeast frataxin homologue (Yfh1). Hum Mol Genet 12: 879-889.
12. Bulteau AL, O'Neill HA, Kennedy MC, Ikeda-Saito M, Isaya G, et al. (2004) Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 305: 242-245.
13. Yoon T, Cowan JA, (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J Biol Chem 279: 25943-25946.
14. Ramazzotti A, Vanmansart V, Foury F, (2004) Mitochondrial functional interactions between frataxin and Isu1p, the iron-sulfur cluster scaffold protein, in Saccharomyces cerevisiae. FEBS Lett 557: 215-220.
15. Yoon T, Cowan JA, (2003) Iron-sulfur cluster biosynthesis. Characterization of frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins. J Am Chem Soc 125: 6078-6084.
16. Foury F, Pastore A, Trincal M, (2007) Acidic residues of yeast frataxin have an essential role in Fe-S cluster assembly. EMBO Rep 8: 194-199.
17. Wang T, Craig EA, (2008) Binding of yeast frataxin to the scaffold for Fe-S cluster biogenesis, Isu. J Biol Chem 283: 12674-12679.
18. Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J, et al. (2007) The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol 114: 163-173.
19. Koeppen AH, Morral JA, Davis AN, Qian J, Petrocine SV, et al. (2009) The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol 118: 763-776.
20. Grabczyk E, Mancuso M, Sammarco MC, (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res 35: 5351-5359.
21. Saveliev A, Everett C, Sharpe T, Webster Z, Festenstein R, (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 422: 909-913.
22. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, et al. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2: 551-558.
23. Greene E, Mahishi L, Entezam A, Kumari D, Usdin K, (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 35: 3383-3390.
24. Al-Mahdawi S, Pinto RM, Ismail O, Varshney D, Lymperi S, et al. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet 17: 735-746.
25. Castaldo I, Pinelli M, Monticelli A, Acquaviva F, Giacchetti M, et al. (2008) DNA methylation in intron 1 of the frataxin gene is related to GAA repeat length and age of onset in Friedreich's ataxia patients. J Med Genet 45: 808-812.
26. Rai M, Soragni E, Jenssen K, Burnett R, Herman D, et al. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3: e1958.
27. Xu C, Soragni E, Chou CJ, Herman D, Plasterer HL, et al. (2009) Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol 16: 980-989.
28. Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, et al. (2012) FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 71: 487-497.
29. Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, et al. (1996) The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 59: 554-560.
30. Monros E, Molto MD, Martinez F, Canizares J, Blanca J, et al. (1997) Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet 61: 101-110.
31. De Michele G, Filla A, Criscuolo C, Scarano V, Cavalcanti F, et al. (1998) Determinants of onset age in Friedreich's ataxia. J Neurol 245: 166-168.
32. Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, et al. (1999) Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 87: 168-174.
33. Santoro L, Perretti A, Lanzillo B, Coppola G, De Joanna G, et al. (2000) Influence of GAA expansion size and disease duration on central nervous system impairment in Friedreich's ataxia: contribution to the understanding of the pathophysiology of the disease. Clin Neurophysiol 111: 1023-1030.
34. Sarsero JP, Li L, Wardan H, Sitte K, Williamson R, et al. (2003) Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 5: 72-81.
35. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, et al. (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110: 401-408.
36. Pandolfo M, (2008) Drug Insight: antioxidant therapy in inherited ataxias. Nat Clin Pract Neurol 4: 86-96.
37. Schulz JB, Boesch S, Burk K, Durr A, Giunti P, et al. (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 5: 222-234.
38. Sarsero JP, Li L, Holloway TP, Voullaire L, Gazeas S, et al. (2004) Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice. Mamm Genome 15: 370-382.
39. Puspasari N, Rowley SM, Gordon L, Lockhart PJ, Ioannou PA, et al. (2011) Long range regulation of human FXN gene expression. PLoS One 6: e22001.
40. Sarsero JP, Holloway TP, Li L, McLenachan S, Fowler KJ, et al. (2005) Evaluation of an FRDA-EGFP genomic reporter assay in transgenic mice. Mamm Genome 16: 228-241.
41. Al-Mahdawi S, Pinto RM, Varshney D, Lawrence L, Lowrie MB, et al. (2006) GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 88: 580-590.
42. Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF, (2008) Lateral-flow immunoassay for the frataxin protein in Friedreich's ataxia patients and carriers. Mol Genet Metab 94: 491-497.
43. Narayanan K, Williamson R, Zhang Y, Stewart AF, Ioannou PA, (1999) Efficient and precise engineering of a 200 kb beta-globin human/bacterial artificial chromosome in E. coli DH10B using an inducible homologous recombination system. Gene Ther 6: 442-447.
44. Al-Mahdawi S, Pinto RM, Ruddle P, Carroll C, Webster Z, et al. (2004) GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 84: 301-310.
45. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, et al. (2001) Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A 98: 14595-14600.
46. Corish P, Tyler-Smith C, (1999) Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 12: 1035-1040.
47. Wermuth CG, (2006) Selective optimization of side activities: the SOSA approach. Drug Discov Today 11: 160-164.
48. Boulikas T, Vougiouka M, (2003) Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep 10: 1663-1682.
49. Ghazizadeh M, (2003) Cisplatin may induce frataxin expression. J Nippon Med Sch 70: 367-371.
50. Ulukan H, Swaan PW, (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62: 2039-2057.
51. Sohn YS, Breuer W, Munnich A, Cabantchik ZI, (2008) Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 111: 1690-1699.
52. Pirola L, Frojdo S, (2008) Resveratrol: one molecule, many targets. IUBMB Life 60: 323-332.
53. Baur JA, Sinclair DA, (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
54. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, et al. (2007) Resveratrol: from basic science to the clinic. Cell Cycle 6: 2495-2510.
55. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
56. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
57. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
58. Yang T, Fu M, Pestell R, Sauve AA, (2006) SIRT1 and endocrine signaling. Trends Endocrinol Metab 17: 186-191.
59. Beher D, Wu J, Cumine S, Kim KW, Lu SC, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
60. Dai H, Kustigian L, Carney D, Case A, Considine T, et al. (2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 285: 32695-32703.
61. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118.
62. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, et al. (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
63. Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, et al. (2009) Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum Mol Genet 18: 2452-2461.
64. Marmolino D, Manto M, Acquaviva F, Vergara P, Ravella A, et al. (2010) PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia. PLoS One 5: e10025.
65. O'Hagan KA, Cocchiglia S, Zhdanov AV, Tambuwala MM, Cummins EP, et al. (2009) PGC-1alpha is coupled to HIF-1alpha-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells. Proc Natl Acad Sci U S A 106: 2188-2193.
66. Marmolino D, Acquaviva F, Pinelli M, Monticelli A, Castaldo I, et al. (2009) PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy. Cerebellum 8: 98-103.
67. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, et al. (2009) Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 53Suppl 1: S7-15.
68. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, et al. (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447.
69. Mokni M, Elkahoui S, Limam F, Amri M, Aouani E, (2007) Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem Res 32: 981-987.
70. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK, (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382.
71. la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, et al. (2010) Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 49: 449-454.
72. Rai M, Soragni E, Chou CJ, Barnes G, Jones S, et al. (2010) Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 5: e8825.
73. Sandi C, Pinto RM, Al-Mahdawi S, Ezzatizadeh V, Barnes G, et al. (2011) Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 42: 496-505.
74. Soragni E, Xu C, Cooper A, Plasterer HL, Rusche JR, et al. (2011) Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases. Methods Mol Biol 793: 495-508.
75. Acquaviva F, Castaldo I, Filla A, Giacchetti M, Marmolino D, et al. (2008) Recombinant Human Erythropoietin Increases Frataxin Protein Expression Without Increasing mRNA Expression. Cerebellum.
76. Boesch S, Sturm B, Hering S, Scheiber-Mojdehkar B, Steinkellner H, et al. (2008) Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial. Mov Disord 23: 1940-1944.
77. Sacca F, Piro R, De Michele G, Acquaviva F, Antenora A, et al. (2011) Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. Mov Disord 26: 739-742.
78. Tomassini B, Arcuri G, Fortuni S, Sandi C, Ezzatizadeh V, et al. (2012) Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet 21: 2855-2861.